Literature DB >> 34112241

Seven-year follow-up of posterior chamber phakic intraocular lens with central port design.

Luis Fernández-Vega-Cueto1, Belén Alfonso-Bartolozzi1, Carlos Lisa1, David Madrid-Costa2, José F Alfonso3.   

Abstract

BACKGROUND: To assess the clinical outcomes of the Visian Implantable Collamer Lens (ICL) with a central port throughout 7 years of follow-up.
METHODS: Eighty-four eyes of 52 patients were evaluated over a follow-up period of 7 years after V4c ICL implantation. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, intraocular pressure (IOP), endothelial cell density (ECD) and vault were analysed.
RESULTS: The mean postoperative UDVA (logMAR) was 0.04 ± 0.11, 0.13 ± 0.19 and 0.17 ± 0.23 at 1-, 5- and 7-years, respectively (P < 0.0001). The mean CDVA (logMAR) remains unchanged throughout a 7-year follow-up period (0.02 ± 0.08 and 0.02 ± 0.08, at 5- and 7-years, respectively, P = 0.2). At all follow-up visits, more than 95% of the eyes achieved a CDVA of 20/25 or better and more than 85% a CDVA of 20/20. At the end of the follow-up (7 years), no eye lost more lines of CDVA, 56 eyes (66.7%) and 28 eyes (33.3%) gained lines of CDVA. At 7-years, the spherical equivalent was - 0.62 ± 0.62 D. No significant increase in IOP (> 20 mmHg or an increase higher than 5 mmHg) occurred in any case throughout the 7-year of follow-up. The loss in ECD from the preoperative baseline at the last follow-up visit was 2.6%. No intraoperative or postoperative complications or adverse events occurred during the follow-up period.
CONCLUSIONS: The outcomes of this study show the long-term viability of the V4c ICL implantation as a surgical option for the correction of myopia.

Entities:  

Keywords:  ICL; Implantable Collamer Lens; Long-term; Myopia

Year:  2021        PMID: 34112241     DOI: 10.1186/s40662-021-00247-1

Source DB:  PubMed          Journal:  Eye Vis (Lond)        ISSN: 2326-0254


  8 in total

Review 1.  Analysis of perioperative problems related to intraocular Implantable Collamer Lens (ICL) implantation.

Authors:  Hao Zhang; Rui Gong; Xiaolan Zhang; Yingping Deng
Journal:  Int Ophthalmol       Date:  2022-06-22       Impact factor: 2.029

2.  Clinical Prediction of Inadequate Vault in Eyes With Thick Lens After Implantable Collamer Lens Implantation Using Iris Morphology.

Authors:  Zhikun Yang; Lihui Meng; Xinyu Zhao; Youxin Chen; Yan Luo
Journal:  Front Med (Lausanne)       Date:  2022-06-09

3.  Assessment of biosafety and implantation feasibility of novel phakic refractive lens.

Authors:  Shaohua Zhang; Chang Huang; Huamao Miao; Junyao Wu; Chao Xing; Zhaoxing Dai; Jianguo Sun
Journal:  Int Ophthalmol       Date:  2022-05-13       Impact factor: 2.029

4.  A Nationwide Multicenter Study on 1-Year Outcomes of Posterior Chamber Phakic Intraocular Lens Implantation for Low Myopia.

Authors:  Kazutaka Kamiya; Kimiya Shimizu; Akihito Igarashi; Yoshihiro Kitazawa; Takashi Kojima; Tomoaki Nakamura; Kazuo Ichikawa; Sachiko Fukuoka; Kahoko Fujimoto
Journal:  Front Med (Lausanne)       Date:  2022-05-04

5.  Eight-Year Outcomes of Implantation of Posterior Chamber Phakic Intraocular Lens With a Central Port for Moderate to High Ametropia.

Authors:  Kazutaka Kamiya; Kimiya Shimizu; Masahide Takahashi; Wakako Ando; Hideki Hayakawa; Nobuyuki Shoji
Journal:  Front Med (Lausanne)       Date:  2021-12-16

6.  Low Diopter Phakic Implantable Collamer Lens: Refractive and Visual Outcomes in Low Myopia and Myopic Astigmatism.

Authors:  Ernesto Alonso-Juárez; Daniel Velázquez-Villoria
Journal:  Clin Ophthalmol       Date:  2022-09-02

7.  Three-year follow-up of posterior chamber phakic intraocular lens with a central port design after deep anterior lamellar keratoplasty.

Authors:  Belén Alfonso-Bartolozzi; Carlos Lisa; Luis Fernández-Vega-Cueto; Begoña Baamonde; David Madrid-Costa; José F Alfonso
Journal:  Eye Vis (Lond)       Date:  2022-09-07

8.  Vertically Fixated Posterior Chamber Phakic Intraocular Lens Implantation Through a Superior Corneal Incision.

Authors:  Kazutaka Kamiya; Wakako Ando; Hideki Hayakawa; Satoshi Gotoda; Nobuyuki Shoji
Journal:  Ophthalmol Ther       Date:  2022-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.